跳至主要内容
临床试验/NCT00092170
NCT00092170已完成2 期

A Prospective, Multicenter, Randomized, Open-Label, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of Ertapenem Sodium ( MK0826) Versus Ticarcillin/Clavulanate in the Treatment of Hospital-Acquired Pneumonia, Complicated Intra-Abdominal Infections, and Acute Pelvic Infections in Pediatric Patients

Merck Sharp & Dohme LLC0 个研究点目标入组 100 人开始时间: 2002年3月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
100
主要终点
Efficacy response at post treatment follow up assessment. Clinical and/or laboratory drug-related SAEs during study drug therapy plus 14 days post therapy

研究概览

简要总结

The purpose of this study is to determine the effect of an approved medication for adults for an investigational use in pediatric patients 3 months to 17 years for the treatment of complicated intra-abdominal infections or acute pelvic infections.

详细描述

The duration of treatment is 18 months.

研究设计

研究类型
Interventional
分配方式
Randomized
主要目的
Treatment
盲法
None

入排标准

年龄范围
3 Months 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Patients aged 3 months to 17 years with intra-abdominal infection or acute pelvic infection

排除标准

  • Immune problems
  • Kidney problems

结局指标

主要结局

Efficacy response at post treatment follow up assessment. Clinical and/or laboratory drug-related SAEs during study drug therapy plus 14 days post therapy

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验